Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Christopher Goetz and Sue Leurgans.
Christopher Goetz
Connection Strength
4.061
Sue Leurgans
  1. Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: Positive impact on long-term worsening. Mov Disord. 2008 Aug 15; 23(11):1541-5.
    View in: PubMed
    Score: 0.325
  2. Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord. 2008 Apr 15; 23(5):690-9.
    View in: PubMed
    Score: 0.317
  3. Does seasonal variation affect hallucinations in PD? A longitudinal study. Mov Disord. 2006 Jun; 21(6):863-5.
    View in: PubMed
    Score: 0.279
  4. Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients. Mov Disord. 2006 Feb; 21(2):267-70.
    View in: PubMed
    Score: 0.272
  5. Hallucinations and sleep disorders in PD: six-year prospective longitudinal study. Neurology. 2005 Jan 11; 64(1):81-6.
    View in: PubMed
    Score: 0.253
  6. The role of the serotonin system in animal models of myoclonus. Adv Neurol. 2002; 89:244-8.
    View in: PubMed
    Score: 0.205
  7. Posthypoxic myoclonus in the rat: natural history, stability, and serotonergic influences. Mov Disord. 2000; 15 Suppl 1:39-46.
    View in: PubMed
    Score: 0.179
  8. Advantages of a modified scoring method for the Rush Video-Based Tic Rating Scale. Mov Disord. 1999 May; 14(3):502-6.
    View in: PubMed
    Score: 0.170
  9. Sildenafil in the Treatment of Erectile Dysfunction in Parkinson's Disease. Mov Disord Clin Pract. 2017 May-Jun; 4(3):412-415.
    View in: PubMed
    Score: 0.144
  10. Racial differences may influence the role of cholecystokinin polymorphisms in Parkinson's disease hallucinations. Mov Disord. 2011 Aug 01; 26(9):1781-2.
    View in: PubMed
    Score: 0.098
  11. Determinants of quality of life in children with Gilles de la Tourette syndrome. Mov Disord. 2009 May 15; 24(7):1070-3.
    View in: PubMed
    Score: 0.085
  12. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008 Nov 15; 23(15):2129-70.
    View in: PubMed
    Score: 0.083
  13. Evaluating Parkinson's disease patients at home: utility of self-videotaping for objective motor, dyskinesia, and ON-OFF assessments. Mov Disord. 2008 Jul 30; 23(10):1479-82.
    View in: PubMed
    Score: 0.081
  14. Visual hallucinations and symptoms of REM sleep behavior disorder in Parkinsonian tauopathies. Int J Geriatr Psychiatry. 2008 Jun; 23(6):598-603.
    View in: PubMed
    Score: 0.080
  15. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord. 2007 Jan; 22(1):41-7.
    View in: PubMed
    Score: 0.073
  16. Motor function in Parkinson's disease and supranuclear palsy: simultaneous factor analysis of a clinical scale in several populations. BMC Med Res Methodol. 2006 Jun 13; 6:26.
    View in: PubMed
    Score: 0.070
  17. The malignant course of "benign hallucinations" in Parkinson disease. Arch Neurol. 2006 May; 63(5):713-6.
    View in: PubMed
    Score: 0.069
  18. Gilles de la Tourette syndrome: patient's knowledge and concern of adverse effects. Mov Disord. 2006 Feb; 21(2):248-52.
    View in: PubMed
    Score: 0.068
  19. Single-blind clinical trial of psychotherapy for treatment of psychogenic movement disorders. Parkinsonism Relat Disord. 2006 Apr; 12(3):177-80.
    View in: PubMed
    Score: 0.068
  20. Rating scale for psychogenic movement disorders: scale development and clinimetric testing. Mov Disord. 2005 Dec; 20(12):1592-7.
    View in: PubMed
    Score: 0.067
  21. Short-term and practice effects of metronome pacing in Parkinson's disease patients with gait freezing while in the 'on' state: randomized single blind evaluation. Parkinsonism Relat Disord. 2004 Dec; 10(8):507-10.
    View in: PubMed
    Score: 0.063
  22. Objective assessments of longitudinal outcome in Gilles de la Tourette's syndrome. Neurology. 2003 Oct 14; 61(7):936-40.
    View in: PubMed
    Score: 0.058
  23. Wheeled and standard walkers in Parkinson's disease patients with gait freezing. Parkinsonism Relat Disord. 2003 Oct; 10(1):9-14.
    View in: PubMed
    Score: 0.058
  24. Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Arch Neurol. 2003 Apr; 60(4):529-33.
    View in: PubMed
    Score: 0.056
  25. Progression of gait, speech and swallowing deficits in progressive supranuclear palsy. Neurology. 2003 Mar 25; 60(6):917-22.
    View in: PubMed
    Score: 0.056
  26. Progressive worsening of spatial and chromatic processing deficits in Parkinson disease. Arch Neurol. 2002 Aug; 59(8):1249-52.
    View in: PubMed
    Score: 0.053
  27. Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology. 2002 May 14; 58(9):1418-22.
    View in: PubMed
    Score: 0.053
  28. Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease. Mov Disord. 2002 Mar; 17(2):283-8.
    View in: PubMed
    Score: 0.052
  29. Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology. 2001 Dec 11; 57(11):2078-82.
    View in: PubMed
    Score: 0.051
  30. Early morning off-medication dyskinesias, dystonia, and choreic subtypes. Arch Neurol. 2001 Sep; 58(9):1379-82.
    View in: PubMed
    Score: 0.050
  31. Home alone: methods to maximize tic expression for objective videotape assessments in Gilles de la Tourette syndrome. Mov Disord. 2001 Jul; 16(4):693-7.
    View in: PubMed
    Score: 0.050
  32. Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study. Arch Neurol. 2001 Feb; 58(2):209-13.
    View in: PubMed
    Score: 0.048
  33. Menstrual-related changes in motoric function in women with Parkinson's disease. Neurology. 2000 Nov 28; 55(10):1572-5.
    View in: PubMed
    Score: 0.048
  34. Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease. Arch Neurol. 2000 Oct; 57(10):1461-3.
    View in: PubMed
    Score: 0.047
  35. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology. 2000 Sep 26; 55(6):789-94.
    View in: PubMed
    Score: 0.047
  36. Objective changes in motor function during placebo treatment in PD. Neurology. 2000 Feb 08; 54(3):710-4.
    View in: PubMed
    Score: 0.045
  37. Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease. Mov Disord. 1999 Jan; 14(1):117-21.
    View in: PubMed
    Score: 0.042
  38. The effect of changes in head posture on the patterns of muscle activity in cervical dystonia (CD). Mov Disord. 1998 May; 13(3):490-6.
    View in: PubMed
    Score: 0.040
  39. Diffusion tensor imaging of Parkinson's disease, atypical parkinsonism, and essential tremor. Mov Disord. 2013 Nov; 28(13):1816-22.
    View in: PubMed
    Score: 0.028
  40. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients. Clin Neuropharmacol. 2009 Jul-Aug; 32(4):189-92.
    View in: PubMed
    Score: 0.022
  41. Transcultural comparison of psychogenic movement disorders. Mov Disord. 2005 Oct; 20(10):1343-5.
    View in: PubMed
    Score: 0.017
  42. Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system. Arch Neurol. 2004 Aug; 61(8):1280-4.
    View in: PubMed
    Score: 0.015
  43. Estrogen, progesterone, and tic severity in women with Gilles de la Tourette syndrome. Neurology. 2001 Oct 23; 57(8):1519.
    View in: PubMed
    Score: 0.013
  44. Estrogen supplementation in the posthypoxic myoclonus rat model. Clin Neuropharmacol. 2001 Jan-Feb; 24(1):58-61.
    View in: PubMed
    Score: 0.012
  45. Application of the Unified Parkinson's Disease Rating Scale in progressive supranuclear palsy: factor analysis of the motor scale. Mov Disord. 2000 Mar; 15(2):276-9.
    View in: PubMed
    Score: 0.011
  46. "On" freezing in Parkinson's disease: resistance to visual cue walking devices. Mov Disord. 2000 Mar; 15(2):309-12.
    View in: PubMed
    Score: 0.011
  47. Effects of central dopaminergic stimulation by apomorphine on speech in Parkinson's disease. Neurology. 2000 Jan 25; 54(2):458-62.
    View in: PubMed
    Score: 0.011
  48. Animal model of posthypoxic myoclonus: effects of serotonergic antagonists. Neurology. 1999 Jan 01; 52(1):16-21.
    View in: PubMed
    Score: 0.010
  49. Poor visual discrimination and visual hallucinations in Parkinson's disease. Clin Neuropharmacol. 1998 Sep-Oct; 21(5):289-95.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.